RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
Disease control Not yet recruitingThis study tests whether a new drug called SCTB35, combined with standard chemotherapy, works better than the current standard treatment (rituximab plus chemo) for people whose diffuse large B-cell lymphoma has come back or stopped responding to prior therapy. About 101 adults ag…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for Hard-to-Treat lymphoma: drug cocktail enters human trials
Disease control Not yet recruitingThis study tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) in 62 adults with relapsed or refractory diffuse large B-cell lymphoma. The goal is to find the safest dose and see if the combo can shrink tumors. It's an early-phase t…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 26, 2026 14:55 UTC